Breakthrough HIV Drug Blocked as Funding Model Struggles
核心洞察
NICE has issued draft guidance declining NHS commissioning of lenacapavir, the twice-yearly injectable HIV (搜索) prevention drug already approved by the MHRA and prescribed privately.
The draft rests on absent head-to-head data versus GSK's two-monthly injectables, mismatched trial populations, and a price above NICE's cost effectiveness threshold.
Charities including Terrence Higgins Trust (搜索) and HIV i-Base (搜索) note the clinical case is uncontested, and a November NICE meeting leaves room for a confidential discount.
The Medicines and Healthcare products Regulatory Agency (搜索) has approved lenacapavir, a twice-yearly injectable offering near total protection against HIV (搜索) infection, and private clinics in the UK already prescribe it. The National Institute for Health and Care Excellence (搜索) has now said no, at least for now, in draft guidance, leaving patients in the gap between regulatory approval and NHS reimbursement.
NICE's draft rests on three grounds: there is no head-to-head trial against the existing two-monthly injectable options from GSK, so the comparative clinical case is incomplete; the population studied in lenacapavir's trials does not map cleanly onto UK HIV (搜索) risk groups; and the price, before any confidential discount, exceeds what NICE considers reasonable use of public money for the benefit delivered. Sexual health charities, including Terrence Higgins Trust (搜索) and HIV i-Base (搜索), have drawn a parallel with oral PrEP, which faced years of delay before routine NHS commissioning in 2020.
The decision also sits against England's HIV (搜索) Action Plan commitment to end new transmissions by 2030. NICE reviews are iterative, and a November meeting gives both sides room to move, likely through a confidential discount that never appears in the published price. Longer term, the episode tests whether NICE's cost effectiveness threshold, largely unchanged in real terms since the early 2000s, still fits long-acting injectables arriving with premium pricing across HIV prevention, contraception and weight management.
Source: Distilled Post